Answers are grounded in this paper and cite their sources.
Randomly-selected, sputum-producing patients within the MWCFC represent sputum-producing patients in the CFFPR. They have similar characteristics, lung function and frequencies of pulmonary exacerbations, microbial infections and use of CF-specific treatments. These findings will plausibly make future interpretations of quantitative measurements of inflammatory biomarkers generalizable to sputum-producing patients in the CFFPR.
No takes yet. Share an insight, caveat, or question.
Liou et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: